Analysts Offer Insights on Healthcare Companies: Impedimed Limited (OtherIPDQF) and Mach7 Technologies (OtherTDMMF)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Impedimed Limited (IPDQF – Research Report) and Mach7 Technologies (TDMMF – Research Report) with bullish sentiments.
Protect Your Portfolio Against Market Uncertainty
Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Impedimed Limited (IPDQF)
In a report released today, Scott Power from Morgans maintained a Buy rating on Impedimed Limited, with a price target of A$0.15. The company's shares closed last Thursday at $0.04.
Power has an average return of 14.0% when recommending Impedimed Limited.
According to TipRanks.com, Power is ranked #8478 out of 9504 analysts.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Impedimed Limited with a $0.08 average price target, an 113.9% upside from current levels. In a report issued on April 30, Canaccord Genuity also maintained a Buy rating on the stock with a A$0.09 price target.
Morgans analyst Iain Wilkie maintained a Buy rating on Mach7 Technologies today and set a price target of A$1.37. The company's shares closed last Tuesday at $0.24, equals to its 52-week low of $0.24.
According to TipRanks.com, Wilkie is ranked #8787 out of 9504 analysts.
Mach7 Technologies has an analyst consensus of Strong Buy, with a price target consensus of $0.65, representing a 170.8% upside. In a report issued on April 30, Wilsons also maintained a Buy rating on the stock with a A$0.85 price target.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
20 minutes ago
- Business Insider
Stifel Nicolaus Sticks to Their Hold Rating for Boyd Gaming (BYD)
In a report released yesterday, Steven Wieczynski from Stifel Nicolaus maintained a Hold rating on Boyd Gaming (BYD – Research Report), with a price target of $76.00. The company's shares closed yesterday at $73.93. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Wieczynski is a 5-star analyst with an average return of 10.2% and a 48.35% success rate. Wieczynski covers the Consumer Cyclical sector, focusing on stocks such as Royal Caribbean, Boyd Gaming, and Las Vegas Sands. Currently, the analyst consensus on Boyd Gaming is a Moderate Buy with an average price target of $79.71, a 7.82% upside from current levels. In a report released on May 30, Morgan Stanley also maintained a Hold rating on the stock with a $76.00 price target. Based on Boyd Gaming's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $991.57 million and a net profit of $110.35 million. In comparison, last year the company earned a revenue of $960.52 million and had a net profit of $136.47 million
Business Insider
20 minutes ago
- Business Insider
Vail Resorts (MTN) Receives a Buy from Stifel Nicolaus
analyst Jeffrey Stantial maintained a Buy rating on Vail Resorts (MTN – Research Report) yesterday and set a price target of $180.00. The company's shares closed yesterday at $155.68. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Stantial covers the Consumer Cyclical sector, focusing on stocks such as Vail Resorts, International Game Technology, and Light & Wonder. According to TipRanks, Stantial has an average return of -1.7% and a 37.80% success rate on recommended stocks. In addition to Stifel Nicolaus, Vail Resorts also received a Buy from Mizuho Securities's Benjamin Chaiken in a report issued on June 6. However, yesterday, Barclays maintained a Sell rating on Vail Resorts (NYSE: MTN). The company has a one-year high of $199.45 and a one-year low of $129.85. Currently, Vail Resorts has an average volume of 729.5K. Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MTN in relation to earlier this year. Most recently, in March 2025, Korch Angela A, the EVP & CFO of MTN bought 185.00 shares for a total of $29,600.00.
Business Insider
41 minutes ago
- Business Insider
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), Addus Homecare (ADUS) and Cytokinetics (CYTK)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on QuidelOrtho (QDEL – Research Report), Addus Homecare (ADUS – Research Report) and Cytokinetics (CYTK – Research Report) with bullish sentiments. Confident Investing Starts Here: QuidelOrtho (QDEL) In a report issued on June 5, Conor McNamara from RBC Capital maintained a Buy rating on QuidelOrtho, with a price target of $60.00. The company's shares closed last Monday at $30.21, close to its 52-week low of $29.74. According to McNamara is ranked 0 out of 5 stars with an average return of -22.5% and a 18.4% success rate. McNamara covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, Bio-Rad Laboratories, and SOPHiA GENETICS. QuidelOrtho has an analyst consensus of Moderate Buy, with a price target consensus of $45.00, which is a 48.4% upside from current levels. In a report issued on June 5, Craig-Hallum also maintained a Buy rating on the stock with a $60.00 price target. Addus Homecare (ADUS) In a report released yesterday, Ryan Daniels from William Blair maintained a Buy rating on Addus Homecare. The company's shares closed last Monday at $116.56. According to Daniels is a 4-star analyst with an average return of 8.4% and a 49.6% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Definitive Healthcare Corp, Pediatrix Medical Group, and Lifestance Health Group. Addus Homecare has an analyst consensus of Strong Buy, with a price target consensus of $135.17, representing a 18.7% upside. In a report issued on June 1, Jefferies also maintained a Buy rating on the stock with a $160.00 price target. Cytokinetics (CYTK) In a report issued on June 5, Leonid Timashev from RBC Capital maintained a Buy rating on Cytokinetics, with a price target of $80.00. The company's shares closed last Monday at $33.13. According to Timashev is a 3-star analyst with an average return of 2.9% and a 42.7% success rate. Timashev covers the Healthcare sector, focusing on stocks such as NewAmsterdam Pharma Company, Perspective Therapeutics, and Edgewise Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cytokinetics with a $75.21 average price target, a 128.3% upside from current levels. In a report issued on May 26, Stifel Nicolaus also maintained a Buy rating on the stock with a $87.00 price target.
